Work

2369P Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1018

Authors: B.A. McGregor, M.T. Campbell, J. Huang, W. Xie, M.A. Bilen, A. Mortazavi, P. Ravi, A. Shah, D. Einstein, G.P. Sonpavde, R.R. McKay, A.O. Siefker-Radtke, J. Bellmunt, T.K. Choueiri

Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Winship Cancer Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Beth Israel Deaconess Medical Center, AdventHealth Orlando, AdventHealth, University of California San Diego, Harvard University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Exelixis, National Comprehensive Cancer Network, Eisai, Astellas Pharma, EMD Serono, National Cancer Institute

OpenAlex ID: W4387807102

FWCI: 0.475

Cites:

Cited by: 2

Related to: 10